Rebates And Discounts Have A Big Impact On US Drug Prices, IQVIA Report Shows

Manufacturer discounts, rebates and other price concessions on brand drugs reduced US drug spending by about 28% to $324.4bn in 2017, according to a report from the IQVIA Institute for Human Data Science released April 19.

The report aims to parse out how rebates and discounts impact drug spending in the US and also explores drug affordability for patients when it comes to the issue of out-of-pocket costs. It builds on an IQVIA report released in March that looked at global drug spending trends, and predicted that the compound annual growth rate for worldwide drug spending will moderate to 3%-6% between 2018 and 2022, due to rebates, discounts and pricing pressure